PCP prophylaxis is necessary for non-HIV patients with specific immunosuppressive conditions
the verdict
SUPPORTED
the evidence backs this
confidence 92/100
Extensive clinical evidence and guidelines demonstrate that PCP prophylaxis is highly effective and necessary for non-HIV patients with specific immunosuppressive conditions, such as hematological malignancies, organ transplants, and prolonged corticosteroid use.
Evidence for · 8
Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients
2014 · cited by 452
A Cochrane systematic review demonstrates that trimethoprim/sulfamethoxazole prophylaxis highly effectively reduces PCP incidence and mortality in non-HIV immunocompromised patients.
See more details
More for · 7
ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients
2016 · cited by 298
ECIL guidelines establish clear indications and drug-of-choice recommendations for primary PCP prophylaxis in high-risk hematological and transplant patient groups.
Population-based studies confirm rising PCP incidence among non-HIV groups such as transplant recipients and those with hematologic malignancies, underscoring prevention needs.
Pneumocystis jirovecii—from a commensal to pathogen: clinical and diagnostic review
2015 · cited by 131
Clinical reviews highlight that PCP remains a significant cause of high mortality in non-HIV immunosuppressed hosts, necessitating careful management.
Epidemiology of Pneumocystis jirovecii Pneumonia and (Non-)use of Prophylaxis
2020 · cited by 43
Retrospective data show that most non-HIV patients who develop PCP had clear guideline indications for prophylaxis that were unfulfilled prior to infection.
Pneumocystis jirovecii pneumonia in non-HIV patients: need for a more extended prophylaxis
2024 · cited by 4
Analysis of non-HIV PCP cohorts emphasizes that a substantial proportion of patients meeting criteria for prophylaxis did not receive it, pointing to a need for better adherence.
Pneumocystis jirovecii pneumonia in solid tumors: High mortality amid frequent corticosteroid exposure and infrequent prophylaxis.
2026 · cited by 0
Studies in solid tumor patients demonstrate high mortality associated with PCP and chronic corticosteroid exposure, highlighting underutilized preventive care.
<i>Pneumocystis jirovecii</i> Pneumonia in Non-HIV, Non-HCT Adults: Real-World Patterns of Overlapping Immunosuppression and PJP-Active Therapy.
2026 · cited by 0
Real-world data indicate that non-HIV patients frequently experience overlapping immunosuppressive exposures, supporting targeted prophylaxis based on overall immunologic burden.